Table 1 Correlation between circRHOBTB3 expression and clinicopathologic characteristics in GC patients
From: Circular RNA circRHOBTB3 acts as a sponge for miR-654-3p inhibiting gastric cancer growth
Characteristics | CircRHOBTB3a expression | |||
|---|---|---|---|---|
n | Low | High | P value | |
Age | ||||
 < 60 | 31 | 11 (39.3%) | 20 (64.5%) | 0.053 |
 ≥ 60 | 28 | 17 (60.7%) | 11 (35.5%) |  |
Gender | ||||
 Male | 41 | 21 (75.0%) | 20 (64.5%) | 0.382 |
 Female | 18 | 7 (25%) | 11 (35.5%) |  |
Tumour size (cm in diameter) | ||||
 ≤ 5 | 47 | 22 (78.6%) | 25 (80.6%) | 0.843 |
 >5 | 12 | 6 (21.4%) | 6 (19.4%) |  |
Location | ||||
 Upper | 13 | 5 (17.9%) | 8 (25.8%) | 0.725 |
 Middle | 10 | 4 (14.3%) | 6 (19.4%) |  |
 Lower | 33 | 17 (60.7%) | 16 (51.6%) |  |
 Whole | 3 | 2 (7.1%) | 1 (3.2%) |  |
Histological stage | ||||
 Well/moderate | 16 | 10 (35.7%) | 6 (19.4%) | 0.158 |
 Poor/undifferentiated | 43 | 18 (64.3%) | 25 (80.6%) |  |
Vascular invasion | ||||
 No | 36 | 19 (67.9%) | 17 (54.8%) | 0.306 |
 Yes | 23 | 9 (32.1%) | 14 (45.2%) |  |
AJCC stage | ||||
 I/II | 18 | 13 (46.4%) | 5 (16.1%) | 0.012* |
 III/IV | 41 | 15 (53.6%) | 26 (83.9%) |  |
T stage | ||||
 T1–3 | 10 | 7 (25.0%) | 3 (9.7%) | 0.223 |
 T4 | 49 | 21 (75.0%) | 28 (90.3%) |  |
N stage | ||||
 N0 | 39 | 19 (67.9%) | 20 (64.5%) | 0.787 |
 N1–3 | 20 | 9 (32.1%) | 11 (35.5%) |  |
M stage | ||||
 M0 | 57 | 26 (92.9%) | 31 (100%) | 0.221 |
 M1 | 2 | 2 (7.1%) | 0 (0.0%) |  |